Sarepta shares up as company updates drug trial
Shares of Sarepta Therapeutics Inc. jumped Wednesday, after the drug developer said its lead candidate, a potential treatment for Duchenne muscular dystrophy, continued to help patients in an extended mid-stage trial.
THE SPARK: The Cambridge, Mass., company said patients taking the treatment, etepl
read more